Metronidazole

Generic Name: Metronidazole

Brand Names: Flagyl, Flagystatin, Likmez, Metrocream, Metrogel, Metrolotion, Nidagel, Noritate, Nuvessa, Pylera, Rosadan, Vandazole

Drug Type: Small Molecule

Chemical Formula: C_₆H_₉N_₃O_₃

CAS Number: 443-48-1

Unique Ingredient Identifier: 140QMO216E

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background: Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.

Indication: Metronidazole is indicated for the treatment of confirmed trichomoniasis caused by Trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis, certain types of amebiasis, and various anaerobic infections. The above anaerobic infections may occur on the skin and skin structures, the abdomen, the heart, reproductive organs, central nervous system, and the respiratory system. Some may also be present in the bloodstream in cases of septicemia. Common infections treated by metronidazole are Bacteroides species infections, Clostridium infections, and Fusobacterium infections, as well as Peptococcus and Peptostreptococcus infections. Topical formulations of metronidazole are indicated for the treatment of inflammatory lesions of rosacea.

It is also used off-label in the treatment of Crohn's disease, as a prophylactic agent after surgery, and in the treatment of Helicobacter pylori infection. It has also been studied in the prevention of preterm births and to treat periodontal disease.

Associated Conditions: Abscess Brain, Abscess, Intra-Abdominal, Anaerobic Bacterial Infection, Bacterial Endocarditis, Bacterial Peritonitis, Bacterial Septicemia, Bacterial Vaginosis (BV), Balantidiasis, Bone and Joint Infections, Central Nervous System Bacterial Infections, Empyema, Endometritis, Endomyometritis, Facial Rosacea, Giardiasis, Gynecological Infection, Helicobacter Pylori Infection, Inflammatory Papule, Inflammatory pustules, Liver Abscess, Amebic, Lower respiratory tract infection bacterial, Lung Abscess, Meningitis, Mixed Vaginal Infections, Mixed Vaginal Infections caused by Trichomonas Vaginalis, candida albicans, Periodontitis, Pneumonia, Postoperative Infections, Pouchitis, Skin and skin structure infections, Tetanus, Trichomonas Vaginitis, Tubo-ovarian abscess, Vaginal Candidiasis, Vaginitis Trichomonal, Vulvovaginitis, Acute Intestinal amebiasis, Asymptomatic Trichomoniasis, Entamoeba histolytica, Hepatic abscess, Intra-abdominal bacterial infections, Post-surgical vaginal cuff infection, Refractory Sinusitis, Symptomatic Trichomoniasis

Clinical Trials

Antibiotic Prophylaxis in Metabolic Bariatric Surgery

Not Applicable

Not yet recruiting

Conditions: Antibiotic Reaction
Wound Infection Superficial
Wound Infection Deep
Bariatric Surgery Candidate
Complication,Postoperative

Interventions: Drug: NACL 0.9% 100 ml
Drug: 2000 mg of Cefazolin
Drug: 500 mg of Metronidazole IV

First Posted Date: 2024-07-19

Last Posted Date: 2024-07-31

Lead Sponsor: General Committee of Teaching Hospitals and Institutes, Egypt

Target Recruit Count: 3352

Registration Number: NCT06510452

Locations: 🇳🇱
WeightWorks clinics, Amersfoort, Utrecht, Netherlands
🇪🇬
Madina Women's Hospital, Alexandria, Egypt

Optimization of Bacterial Vaginosis Treatment in Women of Reproductive Age

Phase 4

Recruiting

Conditions: Bacterial Vaginosis

Interventions: Drug: Longidaza
Drug: Metronidazole 500 mg

First Posted Date: 2024-06-13

Last Posted Date: 2025-04-09

Lead Sponsor: I.M. Sechenov First Moscow State Medical University

Target Recruit Count: 100

Registration Number: NCT06458543

Locations: 🇷🇺
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
🇷🇺
LLC "Family polyclinic No. 4" Korolev, Korolev, Russian Federation

Metronidazole SC Penetrance With Moisturizers

Not Applicable

Recruiting

Conditions: Rosacea, Erythematotelangiectatic

Interventions: Drug: Metronidazole cream
Other: Cetaphil moisturizer
Other: CeraVe moisturizer
Other: Eucerin Healing Lotion moisturizer
Other: Aveeno Calm and Restore Oat Gel moisturizer

First Posted Date: 2024-05-30

Last Posted Date: 2025-03-21

Lead Sponsor: Duke University

Target Recruit Count: 20

Registration Number: NCT06434519

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)

Phase 4

Recruiting

Conditions: Pregnancy, High Risk
Preterm Birth
Preterm Premature Rupture of Membrane

Interventions: Drug: Ampicillin 2 GM Injection
Drug: Ceftriaxone 1000 MG
Drug: Clarithromycin 500mg
Drug: Amoxicillin 250 MG
Drug: Metronidazole 500 mg
Drug: Azithromycin
Drug: Erythromycin

First Posted Date: 2024-05-02

Last Posted Date: 2024-07-29

Lead Sponsor: Ohio State University

Target Recruit Count: 56

Registration Number: NCT06396078

Locations: 🇺🇸
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio, United States

ORal Antibiotics in Acute Mesenteric Ischemia

Phase 3

Recruiting

Conditions: Acute Mesenteric Ischemia

Interventions: Drug: Placebo
Drug: Gentamicin
Drug: Metronidazole

First Posted Date: 2024-04-26

Last Posted Date: 2025-02-19

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 196

Registration Number: NCT06387147

Locations: 🇫🇷
Gastroentérologie-Hépatologie Beaujon, Clichy, France
🇫🇷
Réanimation - Beaujon, Clichy, France
🇫🇷
Chirurgie vasculaire, Paris, France

and more 1 locations

Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth

Phase 4

Not yet recruiting

Conditions: Bacterial Vaginosis
Vaginal Dysbiosis
Premature Delivery

Interventions: Diagnostic Test: Vaginal flora abnormalities screening and quantification using molecular biology technique
Other: Usual Care
Drug: Azithromycine
Drug: Ceftriaxone
Drug: Metronidazole
Drug: Clotrimazole, Vaginal